Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease

摘要

The veins of the lower extremity are equipped with efficient wall, contractile venous smooth muscle (VSM) and competent valves in order to withstand the high venous hydrostatic pressure in the lower limb and allow unidirectional movement of deoxygenated blood towards the heart. The vein wall structure and function are in part regulated by matrix metalloproteinases (MMPs). MMPs are zinc-dependent endopeptidases that are secreted as inactive proMMPs by different cells in the venous wall including fibroblasts, VSM and leukocytes. ProMMPs are activated by other MMPs, proteinases, and other endogenous and exogenous activators. MMPs degrades various extracellular matrix (ECM) proteins including collagen and elastin, and could affect other cellular processes including endothelium-mediated dilation, VSM cell migration and proliferation as well as modulation of Ca²⁺ signaling and contraction in VSM. It is thought that increased lower limb venous hydrostatic pressure increases hypoxia inducible factors and other MMP inducers such as EMMPRIN, leading to increased MMP expression/activity, ECM protein degradation, vein wall relaxation, and venous dilation. Vein wall inflammation and leukocyte infiltration cause additional increases in MMPs, and further vein wall dilation and valve degradation, that could lead to chronic venous disease and varicose veins (VVs). VVs are often presented as vein wall dilation and tortuosity, incompetent venous valves and venous reflux. Different regions of VVs show different MMP levels and ECM proteins with atrophic regions showing high MMP levels/activity and little ECM compared to hypertrophic regions with little or inactive MMPs and abundant ECM. Treatment of VVs includes compression stockings, venotonics, sclerotherapy or surgical removal. However, these approaches do not treat the cause of VVs, and other lines of treatment may be needed. Modulation of endogenous tissue inhibitors of metalloproteinases (TIMPs), and exogenous synthetic MMP inhibitors may provide new approaches in the management of VVs.